55 related articles for article (PubMed ID: 14969795)
1. The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression.
Yang CC; Chu KC; Yeh WM
Urol Oncol; 2004; 22(1):1-6. PubMed ID: 14969795
[TBL] [Abstract][Full Text] [Related]
2. Identification of genes correlated with early-stage bladder cancer progression.
Stone R; Sabichi AL; Gill J; Lee IL; Adegboyega P; Dai MS; Loganantharaj R; Trutschl M; Cvek U; Clifford JL
Cancer Prev Res (Phila); 2010 Jun; 3(6):776-86. PubMed ID: 20501863
[TBL] [Abstract][Full Text] [Related]
3. Fetal haemopoiesis marking low-grade urinary bladder cancer.
Wolk M; Martin JE
Br J Cancer; 2012 Jul; 107(3):477-81. PubMed ID: 22735903
[TBL] [Abstract][Full Text] [Related]
4. Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases.
Li T; Hu W; Jin L; Yin X; Kang D; Piao L
Front Oncol; 2023; 13():1164368. PubMed ID: 37124509
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of expression of VEGFR2, KIT, PDGFR-β, and CDK4 in canine urothelial carcinoma.
Setyo LC; Donahoe SL; Shearer PL; Wang P; Krockenberger MB
J Vet Diagn Invest; 2023 Mar; 35(2):109-115. PubMed ID: 36648148
[TBL] [Abstract][Full Text] [Related]
6. Angioprevention of Urologic Cancers by Plant-Derived Foods.
García-Caballero M; Torres-Vargas JA; Marrero AD; Martínez-Poveda B; Medina MÁ; Quesada AR
Pharmaceutics; 2022 Jan; 14(2):. PubMed ID: 35213989
[TBL] [Abstract][Full Text] [Related]
7. Significance of Vascular Endothelial Growth Factor Expression in the Bladder Urothelial Carcinoma and Its Association with Tumor Grade and Invasiveness.
Sadaf A; Rahman MZ; Bhattacharjee P; Ahamad MSU; Nasreen S
Iran J Pathol; 2021; 16(4):362-369. PubMed ID: 34567184
[TBL] [Abstract][Full Text] [Related]
8. The Interplay between Oxidative Stress, Inflammation and Angiogenesis in Bladder Cancer Development.
Wigner P; Grębowski R; Bijak M; Saluk-Bijak J; Szemraj J
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923108
[TBL] [Abstract][Full Text] [Related]
9. Role of the androgen signaling axis in genitourinary malignancies.
Shinder BM; Shupe A; Lee GT; Stein MN; Kim IY; Singer EA
Transl Cancer Res; 2018 Aug; 7(4):1135-1142. PubMed ID: 30701159
[TBL] [Abstract][Full Text] [Related]
10. A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with
Hahn NM; Bivalacqua TJ; Ross AE; Netto GJ; Baras A; Park JC; Chapman C; Masterson TA; Koch MO; Bihrle R; Foster RS; Gardner TA; Cheng L; Jones DR; McElyea K; Sandusky GE; Breen T; Liu Z; Albany C; Moore ML; Loman RL; Reed A; Turner SA; De Abreu FB; Gallagher T; Tsongalis GJ; Plimack ER; Greenberg RE; Geynisman DM
Clin Cancer Res; 2017 Jun; 23(12):3003-3011. PubMed ID: 27932416
[No Abstract] [Full Text] [Related]
11. Role of angiogenesis in urothelial bladder carcinoma.
Fus ŁP; Górnicka B
Cent European J Urol; 2016; 69(3):258-263. PubMed ID: 27729991
[TBL] [Abstract][Full Text] [Related]
12. The route to personalized medicine in bladder cancer: where do we stand?
Massari F; Ciccarese C; Santoni M; Brunelli M; Conti A; Modena A; Montironi R; Santini D; Cheng L; Martignoni G; Cascinu S; Tortora G
Target Oncol; 2015 Sep; 10(3):325-36. PubMed ID: 25634607
[TBL] [Abstract][Full Text] [Related]
13. Multiple mechanisms mediate resistance to sorafenib in urothelial cancer.
Knievel J; Schulz WA; Greife A; Hader C; Lübke T; Schmitz I; Albers P; Niegisch G
Int J Mol Sci; 2014 Nov; 15(11):20500-17. PubMed ID: 25387078
[TBL] [Abstract][Full Text] [Related]
14. Alternating expression levels of
Płuciennik E; Nowakowska M; Stępien A; Wołkowicz M; Stawiński A; Różański W; Lipiński M; Bednarek AK
Oncol Lett; 2014 Nov; 8(5):2291-2297. PubMed ID: 25295115
[TBL] [Abstract][Full Text] [Related]
15. Optimal treatment for metastatic bladder cancer.
Carballido EM; Rosenberg JE
Curr Oncol Rep; 2014 Sep; 16(9):404. PubMed ID: 25056737
[TBL] [Abstract][Full Text] [Related]
16. CD105 is a more appropriate marker for evaluating angiogenesis in urothelial cancer of the upper urinary tract than CD31 or CD34.
Miyata Y; Sagara Y; Watanabe S; Asai A; Matsuo T; Ohba K; Hayashi T; Sakai H
Virchows Arch; 2013 Nov; 463(5):673-9. PubMed ID: 23975255
[TBL] [Abstract][Full Text] [Related]
17. p53-stabilizing agent CP-31398 prevents growth and invasion of urothelial cancer of the bladder in transgenic UPII-SV40T mice.
Madka V; Zhang Y; Li Q; Mohammed A; Sindhwani P; Lightfoot S; Wu XR; Kopelovich L; Rao CV
Neoplasia; 2013 Aug; 15(8):966-74. PubMed ID: 23908596
[TBL] [Abstract][Full Text] [Related]
18. Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.
Apolo AB; Ostrovnaya I; Halabi S; Iasonos A; Philips GK; Rosenberg JE; Riches J; Small EJ; Milowsky MI; Bajorin DF
J Natl Cancer Inst; 2013 Apr; 105(7):499-503. PubMed ID: 23411591
[TBL] [Abstract][Full Text] [Related]
19. Assessment of control tissue for gene and protein expression studies: a comparison of three alternative lung sources.
Passmore MR; Nataatmadja M; Fraser JF
ScientificWorldJournal; 2012; 2012():523840. PubMed ID: 22593690
[TBL] [Abstract][Full Text] [Related]
20. Novel agents for advanced bladder cancer.
Sonpavde G; Elfiky AA; Rosenberg JE
Ther Adv Med Oncol; 2009 Jul; 1(1):37-50. PubMed ID: 21789112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
